文献速递头颈部肿瘤放疗放疗物理与技术

头颈部黏膜黑色素瘤系列的根治性碳离子放疗:在多学科协作中面向未来

Curative carbon ion radiotherapy in a head and neck mucosal melanoma series: Facing the future within multidisciplinarity.
PubMed 文献 · Radiother Oncol · 2023-11-11

本研究评估了本院收治的局部晚期头颈部黏膜黑色素瘤(HNMM)患者接受碳离子放疗(CIRT)的疗效与毒性。2013年6月至2020年6月共40例患者接受CIRT,处方剂量为65.6-68.8 Gy(RBE),分16次照射。中位随访18个月,2年局部无复发生存率、总生存率、无进展生存率和无远处转移生存率分别为84.5%、58.6%、33.2%和37.3%。晚期≥G3毒性发生率为10%。

要点

  • 40例局部晚期HNMM患者接受CIRT,处方剂量65.6-68.8 Gy(RBE)/16次。
  • 2年LRFS、OS、PFS、DMFS分别为84.5%、58.6%、33.2%、37.3%。
  • 晚期≥G3毒性发生率为10%,CIRT安全且局部有效。

核心结论

  • CIRT在晚期HNMM患者中安全且局部有效,需要前瞻性试验评估靶向/免疫系统治疗对改善OS的作用。

研究设计与样本

  • 单中心研究,纳入2013年6月至2020年6月在本院接受CIRT的40例局部晚期HNMM患者。
  • 处方剂量为65.6-68.8 Gy(RBE),分16次照射。
  • 12例(30%)患者仅接受活检,28例(70%)在CIRT前接受手术切除。
  • 45%的患者在CIRT前后接受免疫治疗,其中89%主要用于远处进展。

主要发现

  • 中位随访18个月,2年局部无复发生存率(LRFS)为84.5%,总生存率(OS)为58.6%,无进展生存率(PFS)为33.2%,无远处转移生存率(DMFS)为37.3%。
  • 单因素分析显示,非复发状态、CIRT前手术次数<2次、从初诊到治疗开始时间<9个月的患者LRFS显著更好;手术与未手术患者之间无显著差异。
  • 复发后接受免疫治疗的患者中位OS更长(17个月 vs 3.6个月,p值<0.001)。
  • 晚期毒性≥G3(按CTCAE 5.0分级)发生于10%的患者。

临床怎么用

  • 作者认为CIRT在晚期HNMM患者中安全且局部有效。
  • 作者认为需要前瞻性试验评估靶向/免疫系统治疗对改善OS的作用。

局限性

  • 需要前瞻性试验评估靶向/免疫系统治疗对改善OS的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate efficacy and toxicity of carbon ion radiotherapy (CIRT) in locally advanced head and neck mucosal melanoma (HNMM) patients treated at our Institute. MATERIALS AND METHODS: Between June 2013 and June 2020, 40 HNMM patients were treated with CIRT. Prescription dose was 65.6-68.8 Gy relative biological effectiveness [RBE] in 16 fractions. Twelve (30%) patients received only biopsy, 28 (70%) surgical resection before CIRT. Immunotherapy was administered before and/or after CIRT in 45% of patients, mainly for distant progression (89%). RESULTS: Median follow-up was 18 months. 2-year Local Relapse Free Survival (LRFS), Overall Survival (OS), Progression Free Survival (PFS) and Distant Metastasis Free Survival (DMFS) were 84.5%, 58.6%, 33.2% and 37.3%, respectively. At univariate analysis, LRFS was significantly better for non-recurrent status, < 2 surgeries before CIRT and treatment started < 9 months from the initial diagnosis, with no significant differences for operated versus unresected patients. After relapse, immunotherapy provided longer median OS (17 months vs 3.6, p-value<0.001). Late toxicity ≥ G3 (graded with CTCAE 5.0 scale) was reported in 10% of patients. CONCLUSION: CIRT in advanced HNMM patients is safe and locally effective. Prospective trials are warranted to assess the role of targeted/immune- systemic therapy to improve OS.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Ronchi S, Cicchetti A, Bonora M, et al. Curative carbon ion radiotherapy in a head and neck mucosal melanoma series: Facing the future within multidisciplinarity. Radiother Oncol. 2023. PMID: 37956889. doi:10.1016/j.radonc.2023.110003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。